| 70 | 0 | 100 |
| 下载次数 | 被引频次 | 阅读次数 |
肾上腺素受体激动剂治疗哮喘的发展历程,为针灸在哮喘新靶标发现及治疗方面提供了多维度启示。本文回顾了肾上腺素受体激动剂治疗哮喘的发展历程,包括从非选择性受体激动剂到β2受体激动剂的精准定位、从短效到超长效受体激动剂的效果改进、从单靶点药到靶点药物的联合使用以及剂型的改变。同时梳理了当前针灸治疗哮喘的进展,如新型靶标药物、针灸联合用药及用药方式探索。在此基础上,还探讨了肾上腺素受体激动剂的发展对针刺治疗哮喘的启示,包括应注重(1)精准化靶向:明确针刺作用靶点以提升治疗效能;(2)协同化治疗:多靶点联合用药以增强疗效;(3)便捷化改良:推动针刺剂型创新以提高患者依从性;(4)循证化发展:加强临床研究以积累高质量证据,以期为针灸治疗哮喘新靶标和新方法研发提供参考和思路。
Abstract：The development of adrenergic agonists(AAs) for asthma has provided important mechanistic insights into acupuncture-based target discovery and treatment strategies.This review describes the historical evolution of AA therapy,including the precise optimization of nonselective to β2-selective agonists,improvement from short-acting to ultra-long-acting agents,shift from targeted monotherapy to combination regimens,and alterations in drug formulation.Additionally,this review summarizes recent advances in acupuncture treatment for asthma,including the development of novel targeted therapies,application of acupuncture-based combination regimens,and optimization of the mode of administration.Taken together,this article discusses key insights from research on AA that inform acupuncture approaches,with a focus on:(1) precision targeting:identifying acupuncture-specific targets to improve efficacy;(2) synergistic treatment:employing multi-target combination regimens to enhance therapeutic outcomes;(3)formulation innovation:advancing acupuncture delivery methods to improve patient compliance;and(4)evidence-based development:strengthening clinical research to generate high-quality evidence to inform the discovery of novel targets and treatment strategies for asthma.
[1]Pijnenburg MW,Nantanda R.Rising and falling prevalence of asthma symptoms.Lancet 2021;398(10311):1542-3.
[2]GBD Chronic Respiratory Disease Collaborators.Prevalence and attributable health burden of chronic respiratory diseases,1990-2017:a systematic analysis for the global burden of disease study 2017.Lancet Respir Med2020;8(6):585-96.
[3]GBD 2015 Chronic Respiratory Disease Collaborators.Global,regional,and national deaths,prevalence,disability-adjusted life years,and years lived with disability for chronic obstructive pulmonary disease and asthma,1990-2015:a systematic analysis for the Global Burden of Disease Study 2015.Lancet Respir Med 2017;5(9):691-706.
[4]Huang K,Yang T,Xu J,Yang L,Zhao JP,Zhang XY,et al.Prevalence,risk factors,and management of asthma in China:a national cross-sectional study.Lancet2019;394(10196):407-18.
[5]Ning JZ.Main data of the seventh national population census.China Statistics2021;2021(05):4-5.
[6]Pavord ID,Beasley R,Agusti A,Anderson GP,Bel E,Brusselle G,et al.After asthma:redefining airways diseases.Lancet 2018;391(10118):350-400.
[7]Ruta VM,Motoc NS,Todea DA,Alexescu TG,Valean D,Cozac S,et al.Modification of exhaled air nitric oxide in patients with asthma-cortisone monotherapy or dual inhalation therapy?Ann Agric Environ Med 2021;28(1):89-93.
[8] Shao SJ.Shao's"five Needles"technique for the treatment of lung and spleen deficiency asthma in remission period(in Chinese).Chin J Rural Med Pharm2011;18:83-4.
[9]Yin LM,Xu YD,Peng LL,Duan TT,Liu JY,Xu Z,et al.Transgelin-2 as a therapeutic target for asthmatic pulmonary resistance.Sci Transl Med2018;10:eaam8604.
[10]World Health Organization.Asthma.2024.Accessed July 14,2025.https://www.who.int/news-room/fact-sheets/detail/asthma.
[11]Gamble J,Stevenson M,McClean E,Heaney LG.The prevalence of nonadherence in difficult asthma.Am J Respir Crit Care Med 2009;180(9):817-22.
[12]Lin JT,Li J,Yu WC,Liu YJ,Liu CT,Chen P,et al.A multicenter,cross-sectional,observational study of budesonide/formoterol maintenance and reliever therapy in real-world settings.Respir Med 2017;127:45-50.
[13]National Asthma Education and Prevention Program.National Asthma Education and Prevention Program.Expert panel report:guidelines for the diagnosis and management of asthma update on selected topics-2002.J Allergy Clin Immunol 2002;110(5 Suppl):S141-219.
[14]El-Husseini ZW,Gosens R,Dekker F,Koppelman GH.The genetics of asthma and the promise of genomics-guided drug target discovery.Lancet Respir Med2020;8(10):1045-56.
[15]Yang YQ,Chen HP,Wang AQ,Liu CY,Feng CM,Li P.Analysis of the effect of acupuncture on 174 cases of asthma.Shanghai J Acupunct Moxibust1994;13:153-4.
[16]Yang YQ,Yin LM,Zhu WL,Wang Y,Xu YD,Chen YJ.The scientific path of target discovery from acupuncture:taking acupuncture for the prevention and treatment of asthma as an example.Chi Sci Bull 2020;65(32):3520-5.
[17]Yin LM,Ulloa L,Yang YQ,Transgelin-2:biochemical and clinical implications in cancer and asthma.Trends Biochem Sci 2019;44(10):885-96.
[18]Crunkhorn S.Asthma:alternative route to airway relaxation.Nat Rev Drug Discov 2018;17(4):241.
[19]Matthews C.The use of adrenalin in acute asthma.Br Med J 1910;1(2564):441.
[20]Suzuki T,Ozaki T,Ninagawa C,Nakamura T.On the activities of the medullary extract of the bovine adrenal gland estimated by some biologic tests,using the adrenaline-noradrenaline mixture as the standard.Tohoku J Exp Med1954;60(2):191-5.
[21]Solis-Cohen S.The use of adrenal substance in the treatment of asthma.J Asthma 1990;27(6):401-6.
[22]Rao Y.The first hormone:adrenaline.Trends Endocrinol Metab2019;30(6):331-4.
[23]Macdermot HE.The use of ephedrin in bronchial asthma.Can Med Assoc J1926;16(4):422-3.
[24]Stewart HH.The use of ephedrine in asthma and whooping-cough.Br Med J1929;1(3554):293-5.
[25]Lee MR.The history of Ephedra(ma-huang).J R Coll Physicians Edinb2011;41(1):78-84.
[26]Ahlquist RP.A study of the adrenotropic receptors.Am J Physiol1948;153(3):586-600.
[27]Muittari A.A brief review of sympathomimetic bronchodilators and a description of a new selective agent,rimiterol hydrobromide.Respiration1978;35(3):173-80.
[28]Cloutier MM,Dixon AE,Krishnan JA,Lemanske RF,Jr Pace W,Schatz M.Managing asthma in adolescents and adults:2020 asthma guideline update from the national asthma education and prevention program.JAMA2020;324(22):2301-17.
[29]Lands AM,Luduena FP,Buzzo HJ.Differentiation of receptors responsive to isoproterenol.Life Sci 1967;6(21):2241-9.
[30]Lands AM,Arnold A,McAuliff JP,Luduena FP,Jr Brown TG.Differentiation of receptor systems activated by sympathomimetic amines.Nature1967;214(5088):597-8.
[31]Arnold A,McAuliff JP,Colella DF,O'Connor WV,Jr Brown TG.The beta-2 receptor mediated glycogenolytic responses to catecholamines in the dog.Arch Int Pharmacodyn Ther 1968;176(2):451-7.
[32]Xing G,Yi C,Dou P,Zhi Z,Lin B,Cheng M.Recent progress in the development of β2 adrenergic receptor agonists:a patent review(2015-2020).Expert Opin Ther Pat 2021;31(3):239-46.
[33]Ullman A,Svedmyr N.Salmeterol,a new long acting inhaled beta 2 adrenoceptor agonist:comparison with salbutamol in adult patients with asthma.Thorax1988;43(9):674-8.
[34]Slaton RM,Cruthirds DL Indacaterol(arcapta neohaler)for chronic obstructive pulmonary disease.Phys Ther 2012;37(2):86-98.
[35]Cockcroft DW,Sears MR.Are inhaled longacting beta2 agonists detrimental to asthma?Lancet Respir Med 2013;1(4):339-46.
[36]Benson RL,Perlman F.Clinical effects of epinephrine by inhalation;a survey.J Allergy 1948;19(2):129-40.
[37]Speizer FE,Doll R,Heaf P.Observations on recent increase in mortality from asthma.Br Med J 1968;1(5588):335-9.
[38]Pauwels R.The clinical use of beta-receptor agonists:for and against.Life Sci1993;52(26):2171-9.
[39]Char DS,Ibsen LM,Ramamoorthy C,Bratton SL.Volatile anesthetic rescue therapy in children with acute asthma:innovative but costly or just costly?Pediatr Crit Care Med 2013;14(4):343-50.
[40]Jalba MS.Three generations of ongoing controversies concerning the use of short acting beta-agonist therapy in asthma:a review.J Asthma2008;45(1):9-18.
[41]Castle W,Fuller R,Hall J,Palmer J.Serevent nationwide surveillance study:comparison of salmeterol with salbutamol in patients with asthma who require regular bronchodilator treatment.BMJ 1993;306(6884):1034-7.
[42]Nelson HS,Weiss ST,Bleecker ER,Yancey SW,Dorinsky PMSMART Study Group.The salmeterol multicenter asthma research trial:a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.Chest 2006;129(1):15-26.
[43]Seymour SM,Lim R,Xia C,Andraca-Carrera E,Chowdhury BA.Inhaled corticosteroids and LABAs-removal of the FDA's boxed warning.N Engl J Med2018;378(26):2461-3.
[44]Chowdhury BA,Seymour SM,Levenson MS.Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma.N Engl J Med2011;364(26):2473-5.
[45]Global Initiative for Asthma.Global strategy for asthma management and prevention,2025.Accessed July 14,2025.http://www.ginasthma.org.
[46]Peters SP,Bleecker ER,Canonica GW,Park YB,Ramirez R,Hollis S,et al.Serious asthma events with budesonide plus formoterol vs.budesonide alone.N Engl J Med 2016;375(9):850-60.
[47]Wang MH,Xie XN.Clinical observation on the treatment of 30 cases of bronchial asthma with budesonide/formoterol inhalation.Jilin Med J2010;31(09):1206-7.
[48]L?tvall J,Langley S,Woodcock A.Inhaled steroid/long-acting beta 2 agonist combination products provide 24 h improvement in lung function in adult patients with asthma.Respir Res 2006;7(1):110.
[49]Papi A,Chipps BE,Beasley R,Panettieri RA Jr,Israel E,Cooper M,et al.Albuterol-budesonide fixed-dose combination Rescue inhaler for asthma.N Engl J Med 2022;386(22):2071-83.
[50]Chipps BE,Israel E,Beasley R,Panettieri RA Jr,Albers FC,Rees R,et al.Albuterol-budesonide pressurized metered dose inhaler in patients with mildto-moderate asthma:results of the DENALI double-blind randomized controlled trial.Chest 2023;164(3):585-95.
[51]Zhou M,YHg Lu,Hao CL,Yu XM,Yang MJ.Preliminary exploration of management path for childhood asthmatic diseases based on prescription behavior of bronchodilators.Chin Pharm J 2025;60(12):1307-12.
[52]Su CH,Lu LS.The development history of inhalation therapy for asthma.Chin J Hosp Pharm 2008;11(08):985-7.
[53]Zhou HY,Zhao H.Nebulization inhalation-the preferred treatment method for respiratory diseases.Health Guide 2022;28(01):14-15.
[54]Wei YZ,Hu LH,Huang HJ,Jia LL,Cao W,Xiang L,et al.Current status and clinical evaluation of medication for childhood asthma:based on the survey results from 46 medical institutions.J Pediatr Pharm 2022;28(09):9-14.
[55]Wu HC,Su H,Zhu C,Wu SB,Cui S,Zhou MQ,Effects of electroacupuncture on pulmonary function and neuronal discharge in the solitary nucleus of mice with bronchial asthma.Shanghai J Acupunct Moxibust 2023;42(11):1207-14.
[56]Peng LL Master Dissertation.Shanghai:Shanghai University of Traditional Chinese Medicine;2018.
[57]Emala CW.Bitter taste receptors:taking a bigger bite of airway smooth muscle pathophysiology.Am J Respir Cell Mol Biol 2019;60(5):492-3.
[58]Deshpande DA,Wang WC,Mcllmoyle EL,Robinett KS,Schillinger RM,An SS,et al.Bitter taste receptors on airway smooth muscle bronchodilate by localized calcium signaling and reverse obstruction.Nat Med2010;16(11):1299-304.
[59]Nayak AP,Shah SD,Michael JV,Deshpande DA.Bitter taste receptors for asthma therapeutics.Front Physiol 2019;10:884.
[60]Menzella F,Lusuardi M,Galeone C,Taddei S,Zucchi L Profile of anti-IL-5mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases.J Asthma Allergy 2015;8:105-14.
[61]Yang YQ,Yin LM,Wang Y,Xu YD,Chen YJ.Discovering a new paradigm for driving research in traditional Chinese medicine.Sci Found Chin2024;38(03):412-18.
基本信息:
中图分类号:R246.1
引用信息:
[1]卢进,冯俊涛,尹磊淼,等.肾上腺素受体激动剂与针刺抗哮喘新靶标:哮喘治疗的回顾与启示（英文）[J].World Journal of Acupuncture-Moxibustion,2025,35(04):269-275.
基金信息:
Supported by National Natural Science Foundation of China:No.82374583;82274646
2025-10-15
2025-10-15